Peptides that immunoactivate the tumor microenvironment

Cancer immunotherapy has achieved positive clinical outcomes and is revolutionizing cancer treatment. However, cancer immunotherapy has thus far failed to improve outcomes for most “cold tumors”, which are characterized by low infiltration of immune cells and immunosuppressive tumor microenvironment...

Full description

Saved in:
Bibliographic Details
Published in:Biochimica et biophysica acta. Reviews on cancer 2021-01, Vol.1875 (1), p.188486-188486, Article 188486
Main Authors: Furukawa, Natsuki, Popel, Aleksander S.
Format: Article
Language:English
Subjects:
Humans
Immuno-oncology
Immunologic Factors - genetics
Immunologic Factors - immunology
Immunomodulation
Immunotherapy
Nanoparticles - chemistry
Nanoparticles - therapeutic use
Neoplasms - immunology
Neoplasms - pathology
Neoplasms - therapy
Peptides - genetics
Peptides - immunology
Peptides - therapeutic use
Therapeutic peptides
Tumor microenvironment
Tumor Microenvironment - drug effects
Tumor Microenvironment - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cancer immunotherapy has achieved positive clinical outcomes and is revolutionizing cancer treatment. However, cancer immunotherapy has thus far failed to improve outcomes for most “cold tumors”, which are characterized by low infiltration of immune cells and immunosuppressive tumor microenvironment. Enhancing the responsiveness of cold tumors to cancer immunotherapy by stimulating the components of the tumor microenvironment is a strategy pursued in the last decade. Currently, most of the agents used to modify the tumor microenvironment are small molecules or antibodies. Small molecules exhibit low affinity and specificity towards the target and antibodies have shortcomings such as poor tissue penetration and high production cost. Peptides may overcome these drawbacks and therefore are promising materials for immunomodulating agents. Here we systematically summarize the currently developed immunoactivating peptides and discuss the potential of peptide therapeutics in cancer immunology.
ISSN:0304-419X
1879-2561
DOI:10.1016/j.bbcan.2020.188486